The primary agenda for the meeting is to consider and approve the company's unaudited financial results for the quarter and half year ended September 30, 2026. The notice states the board will also consider "apart from other agenda items."
In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company's trading window for all Directors and Designated Persons has been closed. The closure is effective from the date of this notice, October 19, 2026, and will remain closed until Friday, November 6, 2026. The trading window will reopen for trading on Monday, November 9, 2026.
The communication was digitally signed and issued by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063) of Zydus Lifesciences Limited.